Table 3.
Multivariable analyses for progression-free survival and overall survival in patients treated with ICI (as monotherapy or in combination).
| Multivariable analysis | ||||||
|---|---|---|---|---|---|---|
| Test variables | PFS | OS | ||||
| HR | 95% CI | P | HR | 95% CI | P | |
| Tumor type | ||||||
| NSCLC (ref.)/others* | 0.60 | 0.44-0.80 | <.001 | 0.58 | 0.42-0.80 | <.001 |
| Treatment lines | ||||||
| 1st(ref.)/ ≥ 2 | 1.44 | 1.10-1.89 | .007 | 1.46 | 1.10-1.93 | .009 |
| ECOG PS | ||||||
| 0-1 (ref.)/ ≥ 2 | 2.30 | 1.53-3.46 | <.001 | 2.30 | 1.53-3.45 | <.001 |
| Metastatic sites | ||||||
| 0-1 (ref.)/ ≥ 2 | 1.55 | 1.05-2.27 | .02 | 1.75 | 1.15-2.68 | .01 |
| Sex | ||||||
| Female (ref.)/ Male | 1.11 | 0.84-1.47 | .46 | 1.40 | 1.03-1.89 | .03 |
| BMI | ||||||
| < 25 (ref.)/ ≥ 25 | 0.94 | 0.71-1.23 | .63 | 0.77 | 0.58-1.02 | .07 |
| Statin use | ||||||
| no (ref.)/ yes | 1.00 | 0.74-1.35 | .99 | 0.88 | 0.64-1.20 | .41 |
| LIPID score | ||||||
| GR (ref.) | ||||||
| IR | 1.26 | 0.87-1.83 | .21 | 1.52 | 1.01-2.28 | .04 |
| PR | 1.82 | 1.14-2.90 | .01 | 2.40 | 1.46-3.94 | <.001 |
All variables referred to baseline characteristics of patients before ICIs start.
*Others: renal cell carcinoma, melanoma, urothelial carcinoma, head and neck cancer, small cell carcinoma, and breast cancer.
Abbreviations: PFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval; NSCLC: non-small cell lung cancer; ECOG PS: Eastern Cooperative Oncology Group Performance Status; BMI: body mass index (kg/m2). LIPID score groups: good risk (GR) group with TC ≥ 200 mg/dl and TG < 150 mg/dl; intermediate risk (IR) group with TC < 200 mg/dl and TG < 150 mg/dl or TC ≥200 mg/dl and TG ≥ 150 mg/dl; poor risk (PR) group with TC < 200 mg/dl and TG ≥ 150 mg/dl.